Bangalore, India, Apr 29: OneSource Specialty Pharma Limited today announced that its partner Dr. Reddy’s Laboratories Ltd., has received a Notice of Compliance from Health Canada for Semaglutide Injection, a generic version of Ozempic®. OneSource serves as the CDMO partner on this program, providing scale-up and manufacturing support.
The partnership is designed to ensure reliable and scalable commercial supply from OneSource’s US-FDA approved flagship manufacturing facility in Bengaluru.
Mr. Neeraj Sharma, CEO & MD, OneSource Speciality Pharma Limited, speaking on the development, said: “We are pleased to announce that our partner Dr. Reddy’s has received approval from Health Canada for Semaglutide Injection, a generic version of Ozempic®. This approval further strengthens our collaboration, combining Dr. Reddy’s expertise in peptide development with OneSource’s CDMO capabilities.”
